This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

University Of Washington's Neuro-Oncology Program To Investigate Cell Therapeutics' Drug Candidate OPAXIO™ (Paclitaxel Poliglumex) Plus Radiotherapy For Glioblastoma Multiforme, A Highly Malignant Brain Cancer

SEATTLE, March 27, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that the University of Washington's ("UW") School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO™ (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy ("RT") to the combination of temozolomide ("TMZ") and RT for patients with newly-diagnosed glioblastoma multiforme ("GBM"), which is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT.  MGMT is active in more than half of patients with glioblastoma and it substantially decreases the effectiveness of standard therapy with TMZ. This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group ("BrUOG") in Providence, Rhode Island. The first patient at UW recently has been enrolled. 

Dr. Maciej Mrugala, Associate Professor of Neurology, Neurological Surgery and Medicine at UW's School Of Medicine and Affiliate Investigator at Fred Hutchinson Cancer Research Center is leading the study at the UW site.

"Patients with glioblastomas are rarely cured, although current standard therapy with RT and TMZ has been shown to prolong survival. A Phase I/II study of paclitaxel poliglumex and TMZ with RT, performed by BrUOG, showed encouraging results with median progression free survival of 13.5 months.  Two of the 4 patients tested retrospectively found to express MGMT had progression free survivals of greater than 16 and 18 months as of June 2011," said Dr. Mrugala. (Jepayalan et al, ASCO 2011).

"The current Phase II Trial randomizes patients 2:1 between paclitaxel poliglumex and standard of care and will only enroll patients with active (unmethylated)  MGMT who are less likely to benefit from TMZ. I brought this study protocol to the attention of my colleagues in the Neuro-Oncology Program because the results of the BrUOG study were intriguing and there is a serious unmet medical need," Dr. Mrugala concluded.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,830.63 +110.71 0.62%
S&P 500 2,091.94 +11.53 0.55%
NASDAQ 5,133.2860 +24.62 0.48%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs